VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
BRIDGEWATER, N.J., June 26, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq:VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced members of VYNE’s management will participate in one-on-one meetings at the Leerink Partners Therapeutics Forum on Immunology and Inflammation (I&I) and Metabolic Diseases on Tuesday, July 9, 2024.